aTyr Pharma, Inc.
ATYR Healthcare Biotechnology
aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024. In the quarter to June 2026, revenue fell 90.8%, EPS grew 50.0%, free cash flow grew 32.2% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ATYR
aTyr Pharma, Inc. (ATYR) EV/Sales
As of 16 October 2026, aTyr Pharma, Inc. (ATYR) trades at a EV/Sales of −3.4×. Over the past ten years it has ranged from −3.4× (October 2026) to 39.8× (July 2025) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.3× | — |
| FY2024 | 15.4× | — |
| FY2023 | −1.0× | — |
| FY2022 | 0.4× | (50.73%) |
| FY2020 | 0.8× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | −1.5× | — |
| Mar 2024 | 3.5× | — |
| Sep 2023 | −0.8× | — |
| Dec 2022 | 0.4× | (50.73%) |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATYR aTyr Pharma, Inc. | −3.4× |
| NEUP Neuphoria Therapeutics Inc. compare | −0.3× |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| DYAI Dyadic International Inc. compare | 4.0× |
| ACGN Aceragen, Inc. compare | 4.1× |
| COCP Cocrystal Pharma, Inc. compare | 8.9× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)